Chemical extraction and direct adsorptive purification of recombinant human antigen Ro52

• Published in: Journal of separation science 2004-05, Vol.27 (7-8), p.589-594
• Main Authors: Saccodossi, Natalia, Cabrera, Rosa B., Oliver, Fernando, Gelmi, Lucila, Magglio, Daniel G., Fernández-Lahore, Héctor M., Leoni, Juliana, Stumpo, Rita R.
• Format: Article
• Language: English
• Subjects: Adsorption; Affinity purification; Analysis; Analytical biochemistry: general aspects, technics, instrumentation; Analytical chemistry; Analytical, structural and metabolic biochemistry; Animal Feed; Autoantigens - isolation & purification; Base Sequence; Biological and medical sciences; Chemical extraction; Chemistry; Chromatographic methods and physical methods associated with chromatography; Cloning, Molecular; DNA Primers; Electrophoresis, Polyacrylamide Gel - methods; Escherichia coli - genetics; Exact sciences and technology; Expanded bed; Fundamental and applied biological sciences. Psychology; General pharmacology; Humans; Immunoblotting; Inclusion bodies; Medical sciences; Pharmacology. Drug treatments; Recombinant Proteins - isolation & purification; Ribonucleoproteins - isolation & purification; Ro52; Spermine
• ISSN: 1615-9306; 1615-9314
• DOI: 10.1002/jssc.200301635

The antigenic protein Ro52 was expressed in the E. coli system harboring a 6×His tag in the form of insoluble inclusion bodies. Direct chemical extraction of the product using 6–8 M urea proved to be effective. Furthermore, the tagged protein was recovered by direct adsorption on Ni2+‐loaded commercial adsorbents derivatized with iminodiacetic acid. Screening experiments in small packed columns revealed that selective binding and elution were possible using a denaturing buffer at pH 4.5. The hydrodynamic evaluation of scaled‐up fluidized systems showed values for the φ (dynamic zone) parameter in the range 0.95–1.00 for fluidization in buffer and in the range 0.70–0.85 for the biomass‐containing feedstock. Removal of macromolecular DNA released by the disrupted biomass was mandatory. Under optimized process conditions good recovery (60–70%) was achieved and a highly purified (95%) product obtained. The purified Ro52 retained its immunoreactivity against sera of patients with systemic lupus erythematosus (SLE) and Sjögren's syndrome‐related disorders. The production and application of new recombinant antigens may contribute to increasing the sensitivity and specificity of the detection of anti‐Ro antibodies in these autoimmune diseases.